ChiCTR2500099145 版本V1.0 版本创建时间2025/03/19 10:13:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500099145 

最近更新日期:

Date of Last Refreshed on:

2025-03-19 10:12:44 

注册时间:

Date of Registration:

2025-03-19 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

COPD患者间质性肺异常与不良预后的关系:一项单中心回顾性队列研究

Public title:

The Relationship between Interstitial Lung Abnormalities and Poor Prognosis in COPD Patients : a single-center retrospective cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

COPD患者间质性肺异常与不良预后的关系:一项单中心回顾性队列研究

Scientific title:

The Relationship between Interstitial Lung Abnormalities and Poor Prognosis in COPD Patients : a single-center retrospective cohort study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李立南 

研究负责人:

魏立平 

Applicant:

Li Linan 

Study leader:

Wei Liping 

申请注册联系人电话:

Applicant telephone:

+86 15626239863

研究负责人电话:

Study leader's telephone:

+86 20 81292556

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

975746587@qq.com

研究负责人电子邮件:

Study leader's E-mail:

weilp8@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市荔湾区逢源正街55号

研究负责人通讯地址:

广州市荔湾区多宝路63号

Applicant address:

55 Fengyuan Central Street, Liwan District, Guangzhou, Guangdong

Study leader's address:

63 Duobao Road, Liwan District, Guangzhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州医科大学附属第三医院

Applicant's institution:

The Third Affiliated Hospital of Guangzhou Medical University

研究负责人所在单位:

广州医科大学附属第三医院

Affiliation of the Leader:

The Third Affiliated Hospital of Guangzhou Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临伦审研(IIT)[2024]第 010 号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广州医科大学附属第三医院临床研究与应用伦理委员会

Name of the ethic committee:

Clinical Research and Application Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-20 00:00:00

伦理委员会联系人:

龙土红

Contact Name of the ethic committee:

Long Tuhong

伦理委员会联系地址:

广州市荔湾区多宝路63号

Contact Address of the ethic committee:

63 Duobao Road, Liwan District, Guangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 81292726

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1269918380@qq.com

研究实施负责(组长)单位:

广州医科大学附属第三医院

Primary sponsor:

The Third Affiliated Hospital of Guangzhou Medical University

研究实施负责(组长)单位地址:

广州市荔湾区多宝路63号

Primary sponsor's address:

63 Duobao Road, Liwan District, Guangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广州医科大学附属第三医院

具体地址:

广州市荔湾区多宝路63号

Institution
hospital:

The Third Affiliated Hospital of Guangzhou Medical University

Address:

63 Duobao Road, Liwan District, Guangzhou

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self selected topic (self-funded)

Target disease:

chronic obstructive pulmonary disease

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

通过阈值分析法识别间质性肺异常(ILA),探讨COPD患者中ILA与基本资料、肺功能及不良预后的关系。  

Objectives of Study:

In this study, we investigated the relationship between interstitial lung abnormalities (ILA) and basic data, lung function and poor prognosis in COPD patients by using threshold analysis to identify ILA.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 明确诊断的COPD患者; 2. 年龄≥20岁; 3. 2019年1月1日至2023年10月24日期间在门诊至少行一次胸部CT检查; 4. 2019年1月1日至2024年10月24日期间至少行一次肺功能检查。

Inclusion criteria

1. patients with COPD with a clear diagnosis; 2. Age >= 20 years old; 3. At least one chest CT examination in the outpatient clinic from January 1, 2019 to October 24, 2023; 4. At least one pulmonary function test from January 1, 2019 to October 24, 2024.

排除标准:

①肺癌; ②结缔组织病; ③传染病,包括分枝杆菌病和曲霉病; ④心力衰竭; ⑤胸部CT可见中到大量胸水、气胸,大片实变占位 ; ⑥化疗; ⑦全身性糖皮质激素治疗; ⑧曾行胸外科手术治疗。

Exclusion criteria:

1.. lung cancer; 2 connective tissue disease; 3 infectious diseases, including mycobacterial disease and aspergillosis; 4 heart failure; 5 Chest CT showed moderate to large pleural effusion, pneumothorax, and large consolidation masses; 6 chemotherapy; 7 systemic glucocorticoid therapy; 8 Thoracic surgery.

研究实施时间:

Study execute time:

From 2024-11-20 00:00:00 To 2025-11-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-11-20 00:00:00 To 2024-12-20 00:00:00  

干预措施:

Interventions:

组别:

间质性肺异常组

样本量:

35

Group:

Interstitial lung anomalies group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

非间质性肺异常组

样本量:

35

Group:

Non-interstitial lung anomalies group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

广州医科大学附属第三医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hospital of Guangzhou Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

胸部CT平扫结果

指标类型:

主要指标

Outcome:

Chest CT scan

Type:

Primary indicator

测量时间点:

2019年1月1日至2023年10月24日期间行胸部CT平扫,2019年1月1日至2024年10月24日期间行肺功能检查

测量方法:

标准的放射科检查及软件定量分析方法

Measure time point of outcome:

Chest CT scan was performed from January 1, 2019 to October 24, 2023

Measure method:

Standard methods of radiological examination, software quantitative analysis

指标中文名:

因COPD急性加重(主要诊断)而住院的情况

指标类型:

主要指标

Outcome:

Hospitalization due to an acute exacerbation of COPD (primary diagnosis).

Type:

Primary indicator

测量时间点:

2019年1月1日至2024年10月24日

测量方法:

使用广州医科大学附属第三医院住院病历系统进行既往病历查询

Measure time point of outcome:

January 1, 2019 to October 24, 2024

Measure method:

The inpatient medical record system of the Third Affiliated Hospital of Guangzhou Medical University was used to query past medical records

指标中文名:

肺功能检查结果

指标类型:

主要指标

Outcome:

pulmonary function test results

Type:

Primary indicator

测量时间点:

2019年1月1日至2024年10月24日期间行肺功能检查

测量方法:

标准的肺功能检查方法

Measure time point of outcome:

pulmonary function tests were performed from January 1, 2019 to October 24, 2023

Measure method:

pulmonary function test

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

计划在研究公开发表6个月后将数据上传到国家生物信息中心(https://ngdc.cncb.ac.cn/gsub/)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

It is planned to upload the data to the China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/) six months after the study is published

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用EXCEL表登记每个患者的基本情况,具体数据情况,并专人管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use EXCEL to register the basic information and specific data of each patient, and manage it by special personnel.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-03-19 10:12:44